Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

You are using software which is blocking our advertisements (adblocker).

As we provide the news for free, we are relying on revenues from our banners. So please disable your adblocker and reload the page to continue using this site.
Thanks!

Click here for a guide on disabling your adblocker.

Sign up for our daily Newsletter and stay up to date with all the latest news!

Subscribe I am already a subscriber

AU: Affinity Corp Australia fined $66,600 for alleged unlawful advertising of cannabis products

The Therapeutic Goods Administration (TGA) has issued 5 infringement notices totalling $66,600 to Affinity Corp Australia Pty Ltd for the alleged unlawful advertising of medicinal cannabis products.

The company allegedly promoted the use of unapproved prescription-only medicinal cannabis products, including their own products.

Businesses can only advertise prescription-only medicines exclusively to health professionals and not to the public.

The TGA facilitates legal pathways for doctors to prescribe medicinal cannabis products to patients. Advertising of prescription-only medicines directly to consumers undermines the doctor-patient relationship and may create an inappropriate demand for medicines which may not be right for the individual.

Ensuring compliance with the import, advertising and supply requirements of the Therapeutic Goods Act in relation to medicinal cannabis is a priority for the TGA. We will continue to investigate and take action in relation to alleged non-compliant advertising of medicinal cannabis products to the public. The TGA has published several medicinal cannabis resources for consumers, health professionals and businesses.

Source: tga.gov.au

Publication date: